Posted by Michael Wonder on 28 Sep 2018
Decision to fund sapropterin
28 September 2018 - PHARMAC is pleased to announce a decision to list sapropterin (Kuvan), a treatment for the rare condition phenylketonuria, for women who are pregnant or actively planning a pregnancy and require pharmacological support to manage phenylketonuria in pregnancy.
Sapropterin will be funded from 1 November 2018, through an agreement with BioMarin Pharmaceutical Australia.
